OncRef

Clinical Trial: NCT04214262

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-10-06

Study Overview

Brief Summary

This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving atezolizumab and radiation therapy may work better than radiation therapy alone in treating patients with early non-small cell lung cancer.

Official Title

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Conditions

Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8

Intervention / Treatment

  • Drug: Atezolizumab
  • Procedure: Biospecimen Collection
  • Procedure: Computed Tomography
  • Other: Fludeoxyglucose F-18
  • Procedure: Positron Emission Tomography
  • Other: Quality-of-Life Assessment
  • Other: Questionnaire Administration
  • Radiation: Stereotactic Body Radiation Therapy

Other Study ID Numbers

  • NCI-2019-08627
  • NCI-2019-08627
  • S1914
  • S1914
  • U10CA180888

Start Date (Actual)

2020-08-13

Primary Completion Date (Actual)

2024-08-24

Study Completion Date (Estimated)

2027-06-09

Enrollment (Actual)

417

Study Type

Interventional

Phase

Phase 3